Pharma channel feed – Endpoints News

Pharma channel feed

BioMarin scales back launch for hemophilia gene therapy, pitches path to profitability

9 months ago

Bristol Myers to cut more jobs at headquarters as part of announced restructure

9 months ago

Q&A: Genentech's new CEO on AI, IRA and radiopharma

9 months ago

What the meltdown in the stock market means for biotech and pharma

9 months ago

FDA wants new trial of Actinium’s radioactive iodine drug, company to seek partner

9 months ago

Bayer plans label expansion for Kerendia after Phase 3 win in heart failure

9 months ago

Doses of Lilly's blockbuster GLP-1 in shortage have been pulled from FDA supply list

9 months ago

In Japan, sales of Eisai and Biogen's Alzheimer's drug begin to accelerate

9 months ago

Kyowa Kirin divests China unit, prunes discovery and manufacturing work

9 months ago

Agios' late-stage Pyrukynd trial in kids with rare blood disorder misses primary endpoint

9 months ago

Vertex says about 20 patients have started sickle cell therapy, cuts two rare disease programs

9 months ago

Vir's overhaul brings an end to most virology work — and a beginning with cancer

9 months ago

GSK scores expanded label for Jemperli in first-line endometrial cancer

9 months ago

Despite recent trial success, uniQure plans to cut 65% of staff

9 months ago

RSV market pressure leads to slower launch for Moderna's vaccine

9 months ago

Novartis sues FDA over approval of Entresto generic, following rejection of petition

9 months ago

Biogen CEO sees Alzheimer's drug on right path despite tiny sales, will keep biosimilars business

9 months ago

AbbVie closes $8.7B Cerevel deal in bid to compete with Bristol Myers in schizophrenia

9 months ago

US sales for Merck KGaA’s Bavencio impacted by Padcev/Keytruda momentum in bladder cancer

9 months ago

Updated: Eli Lilly’s tirzepatide reduces risk of heart failure outcomes in Phase 3 study

9 months ago

Judge rejects Novo Nordisk's IRA case as pricing negotiations conclude

9 months ago

Teva factored IRA's next round of negotiations into its growth plans

9 months ago

Takeda defends Alzheimer's pact, TYK2 potential as restructuring is in 'full swing'

9 months ago

Updated: Eisai says Alzheimer's drug keeps working after three years. But weaknesses in study raise questions

9 months ago

First page Previous page 40 41 424344 45 46 Next page Last page